

First Targeted Therapy and Companion Diagnostic Against ADAM8-expressing Cancers

Spin off from Dr. Gail Sonenshein's lab at Tufts University School of Medicine

The Target

ADAM8:

- Cell surface protein
- Drives tumor growth and metastasis
- Independent predictor of poor prognosis in multiple cancers (e.g. breast, colon, stomach)
- Limited expression in normal human tissues


Initial Indication

Triple-Negative Breast Cancer (TNBC):

- ~330,000 new patients and 125,000 deaths yearly world-wide
- Highly aggressive
- Lacks molecular targets for treatment
- Radiation and chemotherapy are ineffective

Leads for both products are available and advancing through preclinical development

Innovative Dual Inhibitory Therapeutic Antibody




Immunohistochemistry (IHC)-based Diagnostic

- Well-established method
- Performed on existing biopsy samples and platforms already in operation worldwide
- Identifies patients most likely to benefit from treatment (~30% of TNBCs)
- Enables rapid adoption of new therapies
- Requires antibody that detects target in IHC

ADP2 Treatment of Pre-Existing TNBC Tumors in Mice


IMPROVES SURVIVAL



REDUCES METASTASIS


Group	Mice with Metastasis	Control	ADP2
Control	10/18		
ADP2	4/18		

Lead IHC Antibody Specifically and Reproducibly Detects ADAM8



Patents filed & exclusive option to license obtained from Tufts University




Finance and Operations Plan Positions Adecto's Products for Phase 1 Clinical Testing



Strong Market Position in a Competitive TNBC Landscape

Landscape

- In the past, little change despite many agents tested
- Recently, some have demonstrated good results, potential to change standard-of-care
→ Low response rates

COMPANY	THERAPEUTIC	TARGET	STAGE	ORR
	ATEZOLIZUMAB	PDL1	ACCELERATED APPROVAL	<u>PHASE III (1ST LINE, mTNBC)</u> 42.6% CHEMO 58.9% CHEMO + ATEZOLIZUMAB
	IMMU-132	TROP2	ACCELERATED APPROVAL	<u>PHASE II (SINGLE-ARM, PRETREATED mTNBC)</u> 33.3%
	PEMBROLIZUMAB	PD1	PHASE III	<u>PHASE II (SINGLE-ARM, PRETREATED mTNBC)</u> 5.7%

ADP2 therapy alone or in combination with other agents, can improve outcome

Market Opportunity

- TNBC therapeutic in US alone is a \$1.5B opportunity:

TARGET MARKET (PATIENTS):

25,000

X

REVENUE/PATIENT/YEAR:

\$63,000

=

REVENUE/YEAR:

\$1.5B

- TNBC diagnostic in US alone is a \$70M opportunity:

TARGET MARKET (PATIENTS):

140,000

X

REVENUE/PATIENT/YEAR:

\$500

=

REVENUE/YEAR:

\$70M

→ This enables sales of therapeutic

- We plan to expand to other ADAM8-driven cancers (colon, stomach, liver, pancreatic, lung) in the future

We estimate over 2 million patients are affected by an ADAM8-driven cancer worldwide

ADP2 Therapy and Companion Diagnostic Will Address Large Unmet Need in Oncology Space

- First-in-class antibody-based ADAM8 inhibitor will target tumor growth and spread
→ improving patient survival
- Companion diagnostic will identify patients who can benefit from ADAM8 inhibition
- Opportunity to impact many cancers with high unmet need



Raising \$8M to fund therapeutic IND-enabling studies

Questions? Contact nora.mineva@adectopharma.com

